Patent · US Active

Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment

US8263344B2 · kind B2 · utility

3Cited by
0References
6Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 7, 2007
Grant dateSep 11, 2012
Priority date
Expiry dateOct 10, 2028

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The present invention relates to a method for determining the susceptibility of a patient tumor cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumor cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.